關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

Global Business NewsGlobal Business News

目前Global Business News文章數, 共 21783 篇 ,以下為 169 - 192 篇 訂閱此列表,掌握最新動態
CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe

CordenPharma is making a record investment of ~€900m over the next 3 years in expanding its peptide platform, both at its Colorado, US site and in Europe. The expansions, covering both existing facilities and new constructions, will meet the pharmaceutical industry's most stringent quality and technical standards for short and long peptide manufacturing, including BLA requirements. The Colorado, US site's expansion will target additional large-scale peptide manufacturing capacity to meet the increasing demand of GLP-1 peptides, resulting from multiple long-term manufacturing contracts totaling ~€3bn, with potential upsides. In Europe, CordenPharma will construct a greenfield site for small to large-scale peptide development and manufacturing, integrated within its global facility network. The company's major expansion plans will act as the driving force behind CordenPharma's €1bn sales target for its Peptide Platform by 2028, reinforcing it as a market leader in the integrated supply of small to large-scale services from APIs to Drug Products (for both Injectable and Oral Peptides). BASEL, Switzerland, July 16, 2024 /PRNewswire/ -- CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its Peptide technology platform. These transformational plans consist of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions designed and built according to the pharmaceutical industry's most stringent quality and technical standards for short and long peptide manufacturing, including Biologics License Applications (BLA) requirements. [Photo by CordenPharma] Large-scale peptide manufacturing in CordenPharma Colorado (USA). The US expansion involves bringing additional Peptide capacity to the CordenPharma Colorado site with the planned construction of a new large-scale manufacturing facility, and an additional increase in manufacturing trains in the existing facility. This is the result of rapidly increasing demand in the Diabetes and Obesity Glucagon-like Peptide 1 (GLP-1) agonist medications market, and comes off the back of multiple, long-term, multiyear contracts totaling ~€3bn, with potential upsides. The European expansion centers on the construction of a new state-of-the-art greenfield facility, with the aim of creating additional Peptide capacity to serve customers from initial early clinical to late-stage commercial manufacturing. The new site will be located in the heart of Europe, fully-integrated within CordenPharma's existing facility network. In 2022, CordenPharma was acquired by Astorg, a leading Pan-European private equity firm, and its ambitious growth plans aim to help the company reach their ~€1bn sales mark for its pioneering Peptide Platform, and ~€1.8bn total group revenue by 2028. Upon completion, the new constructions will be fully integrated within its outstanding network of world-class cGMP manufacturing facilities, along with the dedicated technical and regulatory support by expert teams needed to secure innovators' supply chains with small to large-scale fully-integrated services from APIs to Drug Products. Dr. Michael Quirmbach, President & CEO of the CordenPharma Group comments: "These investments will profoundly strengthen our ability to provide valuable and much needed support to innovators for the benefit of patients. We are honored by the trust our customers have placed in us to deliver expert outsourcing for large multiyear contracts, and our team is proud to contribute decades of peptide manufacturing experience towards these transformative new medicines. In addition, the strong commitment and support of our shareholder Astorg demonstrates their strategic vision for CordenPharma to become the leading CDMO for complex modalities such as Peptides, by offering fully-integrated end-to-end services from APIs to Drug Products (for both Injectable and Oral Peptides)." Dr. Signe Michel, Managing Director at Astorg comments: "We are proud of what Michael and the CordenPharma team have achieved through their striving for operational excellence, customer service and ambitious growth. We are excited about the opportunities ahead and to further strengthen the company's peptide offering across the full drug lifecycle and value chain." Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg comments: "CordenPharma has a unique opportunity to reinforce its leadership position in peptides with unmatched capacity and performance in large scale manufacturing. With the company's proven track record and our investor experience in pharmaceutical services, we feel confident that our latest commitment will help the company seize this opportunity." About CordenPharma CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization. With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency). The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2023 financial year, the organization generated sales of €880 million and had over 3,000 employees. Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn. About Astorg Astorg is a European private equity firm with over €22 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market-leading, global companies mainly headquartered in Europe, providing them with the strategic guidance, governance, and capital they need to achieve their growth goals. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software and technology, business services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan, and Luxembourg. For more information about Astorg: www.astorg.com | Follow Astorg on LinkedIn. CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization. With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency). Photo - https://mma.prnasia.com/media2/2461709/CordenPharma_Peptide_Expansion_Press_Release_16_July_2024___Photo_by_CordenPharma___Large_scale_pept.jpg?p=medium600  Logo - https://mma.prnasia.com/media2/1173757/CordenPharma_Logo_New.jpg?p=medium600

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 49 加入收藏 :
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors

Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets HEIDELBERG, Germany and SEOUL, South Korea, July 17, 2024 /PRNewswire/ -- Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, announced today that it has entered into a license agreement with SK Biopharmaceuticals, a global biotech company, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life's "FL-091" radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers. This licensing deal worth $571.5 million includes an upfront payment, and development and commercial milestones, separate from royalties. Under the terms of the agreement, SK Biopharmaceuticals will in-license the NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091 – as well as its back-up compounds – aimed at developing and commercializing it as an innovative anti-cancer drug. FL-091 is a small-molecule radioligand vector designed to deliver targeted radiation therapy to cancer cells by binding specifically to NTSR1, a receptor protein, which is selectively overexpressed in various types of solid tumors, including colorectal cancer, prostate cancer, and pancreatic cancer. SK Biopharmaceuticals also has a right of first negotiation to license other pre-selected RDC programs of Full-Life. Lanny Sun, Chief Executive Officer of Full-Life, said, "This agreement with SK Biopharmaceuticals highlights the potential of FL-091 in advancing cancer treatment and demonstrates SK Biopharmaceuticals' unwavering commitment to building an oncology business around medical innovation. We look forward to future collaborations with SK Biopharmaceuticals, and to leveraging its expertise and resources to advance radiopharmaceutical therapy. The agreement is aligned with our strategic vision of fostering global partnerships and making a meaningful impact on patients worldwide." Donghoon Lee, Chief Executive Officer and President of SK Biopharmaceuticals, said, "The licensing agreement with Full-Life not only brings the two companies closer together for future collaborations in the fastest rising biotech sector, but also most importantly, pushes SK Biopharmaceuticals forward to become a 'Big Biotech'. Since the introduction of the company's strategy roadmap to venture into radiopharmaceuticals last year, we have been on track toward our envisioned goal. We expect to further unveil and implement business plans for RPT (radiopharmaceutical therapy) this year, and actively pursue clinical development and commercialization in the near future to provide treatment options and create new value worldwide." About FL-091 FL-091 is a novel small-molecule radioligand vector targeting NTSR1 positive solid tumors. Overexpression of NTSR1 has been associated with disease progression of multiple types of cancers, including colorectal, breast, pancreatic, and head and neck cancers. FL-091 radioligands have demonstrated favorable biodistribution profiles and enhanced binding affinity to NTSR1, as well as encouraging anti-tumor activities in preclinical studies. The development of the alpha-emitter therapy candidate 225Ac-FL-091 targeting NTSR1-positive tumors is currently in progress. About Full-Life Technologies Full-Life Technologies ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development. For more information, visit Full-Life's website at www.full-life.com. About SK Biopharmaceuticals SK Biopharmaceuticals focuses on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts. SK Biopharmaceuticals is the first and only Korean company to independently develop and commercialize an antiseizure medication, cenobamate (brand name: XCOPRI®) in the U.S. More than 100,000 patients have been treated globally with cenobamate, developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, Inc., since its launch in the U.S. in 2020. Cenobamate has successfully entered five major regions: North America, Europe, Asia, Central and South America, and the Middle East and North Africa. The company also has a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at www.SKBP.com/eng, and SK Life Science's website at www.SKLifeScienceInc.com.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 53 加入收藏 :
SIBUR Develops Industrial Tourism at Its Green Enterprise

MOSCOW, RUSSIA - Media OutReach Newswire - 17 July 2024 - SIBUR, Russia's largest producer of polymers and rubber, has opened its green enterprise, the Polief plant in the Bashkiriya region, for industrial tourism. Tourists visit Polief to learn about the solar power plant and the technology used to produce plastics from recycled materials. In 2022, Polief began operating a solar power plant consisting of more than 10,000 photovoltaic cells and covering an area equivalent to 10 football fields. The 4.9 MW of solar power generated helps the plant reduce its CO2 and other greenhouse gas emissions by 3,000 tonnes per year. The launch of a solar generation plant at Polief is one of the flagship climate projects within SIBUR's sustainable development strategy. The company has registered the plant in the Qatar-backed Global Carbon Council programme and is preparing to receive internationally recognized carbon credits. Polief uses solar energy to produce eco-friendly products – polymers containing recycled plastic. SIBUR, with the help of partners, has created a network of plastic waste collection points and reverse vending machines for accepting used plastic bottles (PET bottles) across Russia. SIBUR's partners shred these bottles into small pieces (flakes), which are then sent to Polief for further processing. Polief produces PET granules containing up to 30% recycled plastic (rPET) under the Vivilen brand, which are then used to make plastic bottles. Visitors touring the plant can see the production workshop as well as the warehouse with big bags of PET flakes, which are mixed with virgin polymer raw materials during production. Over the past year, Polief has welcomed more than 1,000 tourists, including local residents, young people, and industry professionals interested in eco-friendly production technologies. Polief's capacities make it possible to incorporate up to 34,000 tonnes of recycled plastic waste into new products annually. This prevents up to 1.7 billion used plastic bottles from ending up in landfills. Vivilen rPET is popular with environmentally responsible producers who use plastic bottles made from rPET for bottling water and beverages. SIBUR emphasizes that tours at Polief help Russians understand the importance of sorting and recycling waste and incorporating it into the production of new products. Hashtag: #SIBURThe issuer is solely responsible for the content of this announcement.About SIBURSIBUR is Russia's largest producer of polymers and rubbers. The Company's unique vertically integrated business model enables it to deliver highly competitive products used in the consumer goods and automotive industries, as well as construction, energy, chemistry and other industries across 100 countries. SIBUR helps to reduce CO2 emissions stemming from the burning of oil and gas extraction by-products by processing them into valuable petrochemical products. Learn more at: https://www.sibur.ru/en/

文章來源 : Media OutReach Limited 發表時間 : 瀏覽次數 : 161 加入收藏 :
Russia’s Metalloinvest Plans New Green Metallurgy Project Worth $2 bn

MOSCOW, RUSSIA - Media OutReach Newswire - 17 July 2024 - Metalloinvest, a leading global producer of iron ore products for green steel production, has announced a new investment project worth over $2 billion in central Russia. The company plans to build a plant at its Mikhailovsky GOK unit in the Kursk region, which will produce more than 7 million tonnes of premium-quality iron ore concentrate annually from oxidized iron quartzites – a type of iron ore previously not used in production due to the lack of suitable technologies. Metalloinvest, in collaboration with Russian scientists, has developed a technology for enriching this ore. The new production facility is expected to begin operating in 2028. The concentrate obtained from oxidized quartzites will enable the production of iron ore pellets with an iron content of up to 68% and a low level of silicon dioxide. This product meets the latest market requirements and is an environmentally friendly product for use in green metallurgy based on direct reduction of iron. Direct reduction of iron helps reduce greenhouse gas emissions in the steelmaking industry. Metalloinvest is the world's largest producer of merchant hot briquetted iron – a type of direct reduced iron used to produce steel with a low carbon footprint. The new project will reduce the cost of ore extraction at Mikhailovsky GOK and create 900 jobs. The capacity of the new production facility may be later increased to 11 million tonnes of premium iron ore concentrate per year. The total reserves of oxidized iron quartzites at the Mikhailovsky deposit amount to 2.6 billion tonnes. Hashtag: #MetalloinvestThe issuer is solely responsible for the content of this announcement.

文章來源 : Media OutReach Limited 發表時間 : 瀏覽次數 : 190 加入收藏 :
No Rituals, Just Skills: Octa's Survey Revealed Traders' Attitude to Luck

‘The Lucky ones’: a global traders' surveyKUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 17 July 2024 - Octa, a financial broker with globally recognised licences, has conducted a global survey about traders' attitudes to luck called ‘The lucky ones’. Participants answered questions about their attitude to lucky charms, rituals, and other unorthodox practices that helped them succeed in trading. In this article, we will summarise the survey results that shed light on traders' behaviours and beliefs, providing a unique insight into their mindset. Octa asked traders from Indonesia, Malaysia, and Nigeria about their attitude to good fortune in trading. The results showed that most traders attribute their profits to continuous learning, extensive hands-on experience, and well-executed strategy rather than the agency of higher powers. However, the survey revealed that various unusual behaviours exist among traders, and it would be wrong to suggest that purely ‘rational’ ideas are the only source of truth in the field. The average age of ‘The lucky ones’ survey participants varied from 30 in Nigeria to 39 in Malaysia and 42 in Indonesia, while the respondents' trading experience was virtually the same for all regions and amounted to about two years. In all three focus regions, the share of believers in luck and its attributes was relatively low. In Malaysia, 25% of traders professed to counting on luck in all its forms, as compared with 20% in Nigeria and only 9% in Indonesia. This discrepancy can be explained by obvious differences in cultural background and religious beliefs between the nations. Out of the three countries covered by the survey, Malaysia comes across as the one where traders are most likely to perform various trading rituals before, during, or after their trading sessions. 10% of Malaysian respondents said they employ such practices regularly and attested to the influence of these rituals on the outcomes of their sessions. It is worth noting that in Indonesia, as opposed to Nigeria and Malaysia, traders who use trading rituals devised them by themselves instead of adopting fellow traders' experiences. When asked about the influence of telling signs related to social and political events on market movements, most traders from all three focus countries said they don't consider it significant. Given that, it is only natural that the survey participants pay little attention to alleged market trend indicators like the colour of European Central Bank's ex-president Mario Draghi's tie. A modern approach to trading insights While the respondents' reliance on lucky charms and signs as a trustworthy source of information amounted to less than 20% for all three countries, traders showed a strong preference for obtaining trading signals from outside. Many have a mentor and take part in a traders' community, while others rely on modern tools for trading insights. For example, a number of Indonesian survey participants said they fall back on OctaTrader, Octa's proprietary trading platform, for expert predictions and analytical research. OctaTrader offers its clients an analytical hub called Space. Seamlessly integrated into the OctaTrader application, Space has the form of a customised feed consisting of timely and actionable curated posts filtered by tradable assets, trading style, or other user-defined criteria. Space is designed to deliver decision-making support and contains a wealth of educational content, making trading more data-driven and efficient. Favourite days of the week As experienced traders know, successfully navigating the ebbs and flows of financial markets and knowing when to act and when to keep still is instrumental in achieving consistent gains. Given that, scheduling trading sessions for particular days of the week seems beneficial to most respondents. About half of the survey participants believe Wednesday and Thursday are the most favourable days for trading. This strong preference has a logical rationale behind it. According to Kar Yong Ang, Octa Broker financial market analyst, Wednesday is when the US Federal Reserve announces its interest rate decision, which tends to send ripples throughout the global financial market. In the same vein, Thursday is considered a favourable trading day as it often follows the dynamics established on Wednesday. As such, it seems more predictable than other days of the week. However, this opinion is not uniform. For example, one respondent declared he tends to be especially successful on Mondays and Fridays and will firmly stick to these days no matter what, disregarding any evidence to the contrary. To each their own When asked about their personal trading rituals, traditions, and lucky signs, some respondents gave remarkable and unorthodox answers. Here are some of the things that, according to traders' beliefs, influence good or bad luck in trading: letting their cat sleep on the desk undisturbed sensing the right ear buzzing or feeling an itch in the right palm before or during the session is a sign of the oncoming good fortune relaxing and brewing coffee before the session positively impacts the outcomes bathing with bath soap while repeating positive affirmations helps improve trading results using nutmeg as a lucky charm practising feng shui and using essential oils to clear the mind. It brings calm and leads to abundance. Although some exotic rituals exist among traders, the vast majority put their faith in skill and knowledge rather than luck. As one Nigerian survey participant put it, ‘I don't believe in any rituals, traditions, or stuff like that. I believe in my strategies and strict discipline.’ Hashtag: #OctaThe issuer is solely responsible for the content of this announcement.OctaOcta is an international broker that has been providing online trading services worldwide since 2011. It offers commission-free access to financial markets and various services already used by clients from 180 countries who have opened more than 42 million trading accounts. To help its clients reach their investment goals, Octa offers free educational webinars, articles, and analytical tools. The company is involved in a comprehensive network of charitable and humanitarian initiatives, including the improvement of educational infrastructure and short-notice relief projects supporting local communities. In the APAC region, Octa received the ‘Best Forex Broker Malaysia 2022’ and the ‘Most Reliable Broker Asia 2023’ awards from Global Banking and Finance Review and International Global Forex Awards, respectively.

文章來源 : Media OutReach Limited 發表時間 : 瀏覽次數 : 190 加入收藏 :
Veteran corporate executive Farah Jaafar joins Webull Malaysia's Board of Directors

The vice-president of the FinTech Association of Malaysia brings nearly 30 years of financial experience to her directorship at Webull Malaysia KUALA LUMPUR, Malaysia , July 17, 2024 /PRNewswire/ -- Webull Securities (Malaysia) Sdn. Bhd. ("Webull Malaysia") is pleased to announce the appointment of Farah Jaafar as a new Independent Non-Executive Director of Webull Malaysia.  Veteran corporate executive and former Labuan IBFC CEO Farah Jaafar joins Webull Malaysia as Independent Non-Executive Director. Farah brings a wealth of business and fintech experience and diverse industry perspectives from a 30-year career in various leadership roles in capital markets and financial services organisations. She is the Vice President of the FinTech Association of Malaysia, an organisation that advances national policies, legislation and regulations in fintech and accelerates innovation in the country's financial sector. Farah was the former Chief Executive Officer of premier international financial hub the Labuan International Business and Financial Centre. "We are delighted to welcome Farah to the Webull Malaysia board as we continue to grow our investor community and bring equal investment opportunities to Malaysians. With our learning, sharing and investing philosophy at our core, Webull Malaysia is committed to synergising technology with finance to provide secure, reliable, and intelligent products and services that deliver a seamless trading experience. Farah's expertise, insights and vast fintech experience will be invaluable in our pursuit to make investing an enjoyable and trusted lifelong skill for Malaysians," said Kenneth Chan, Chief Executive Officer, Webull Malaysia. "Webull's focus on investor education and inclusion through state-of-the-art fintech solutions brings a much-needed dimension to Malaysia's capital markets. Our ability to offer access to global equity and derivative markets will provide much-needed investment portfolio diversity for all Malaysian investors. I am excited to contribute my unique experience in fintech, legacy stockbroking and international finance, and support diversity in the boardroom," said Farah. Launched in May, Webull Malaysia is a digital investment platform that provides access to investors of all levels to trade Bursa-listed securities and derivatives contracts such as FCPO and FKLI alongside US-listed stocks and exchange-traded funds (ETFs) via the Webull Malaysia app. Webull Malaysia partners with Elzar Shariah Solutions & Advisory to provide screening for US-listed stocks and exchange-traded funds (ETFs) offered on the platform - shariah-compliant stocks are indicated with a purple crescent icon. About Webull Webull is a leading digital investment platform built on next-generation global infrastructure. The Webull Group is headquartered in St. Petersburg, Florida in the United States and backed by private equity investors located in the United States, Europe, and Asia. Webull serves tens of millions of users from over 180 countries, providing retail investors with 24/7 access to financial markets worldwide. With low-cost trading on a wide range of assets, Webull is revolutionising the way individuals approach investing. Webull Securities (Malaysia) Sdn. Bhd. holds a Capital Markets Services License (Licence No: eCMSL/A0399/2024) under the Capital Market and Services Act 2007 and is regulated by Securities Commission Malaysia. 

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 53 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈